NRTX-1001 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 141 | Mesial temporal lobe epilepsy with hippocampal sclerosis | 1 |
141. Mesial temporal lobe epilepsy with hippocampal sclerosis
Clinical trial : 1 / Drug : 1 - (DrugBank : 0) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05135091 (ClinicalTrials.gov) | June 16, 2022 | 16/11/2021 | FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy | A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE) | Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis | Biological: NRTX-1001;Procedure: Sham Comparator | Neurona Therapeutics | California Institute for Regenerative Medicine (CIRM) | Recruiting | 18 Years | 55 Years | All | 40 | Phase 1/Phase 2 | United States |